Vaxcyte Inc Dossier - Source-backed chat

Vaxcyte Inc

PCVXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.13

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $56.90Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $8.5B

Shares Outstanding 142.2M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vaxcyte is a clinical-stage vaccine innovation company leveraging its proprietary cell-free protein synthesis platform, XpressCF, to develop high-fidelity conjugate vaccines. The company's lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) designed to prevent invasive pneumococcal disease (IPD). VAX-31 is currently the broadest-spectrum PCV candidate in clinical development, targeting approximately 95% of IPD in U.S. adults. With pivotal Phase 3 OPUS-1 trial enrollment complete and topline data expected in Q4 2026, Vaxcyte possesses a highly de-risked pipeline with a clear path toward a Biologics License Application (BLA) submission. Despite being pre-revenue and unprofitable, Vaxcyte's strong balance sheet and potential to disrupt the multi-billion dollar pneumococcal vaccine market make it a compelling buy for growth-oriented biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$67.00

Mean target$109.00

High · most bullish analyst$163.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$38.0010%

VAX-31 fails to meet noninferiority immunogenicity criteria for key serotypes in the OPUS-1 trial, or safety concerns emerge (e.g., higher systemic reactogenicity). This delays the BLA submission significantly, increases cash burn, and forces the company to rely on VAX-24 or earlier-stage pipeline candidates, severely depressing the valuation.

Base CaseCentral scenario

$109.0060%

Matches the consensus mean

VAX-31 demonstrates noninferiority to Prevnar 20 in the OPUS-1 trial in Q4 2026 with a safety profile similar to standard-of-care. OPUS-2 and OPUS-3 trials succeed in H1 2027, keeping the company on track for a standard BLA submission timeline. The stock moves toward the consensus median target as clinical milestones are achieved.

Bull CaseUpside scenario

$163.0030%

VAX-31 OPUS-1 Phase 3 trial meets all primary immunogenicity and safety endpoints with superior coverage compared to Prevnar 20. Concomitant seasonal flu administration (OPUS-2) and previously vaccinated adult (OPUS-3) trials yield positive results in H1 2027, leading to an accelerated BLA submission and rapid market adoption, capturing the majority of the adult PCV market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Broadest-spectrum PCV candidate in clinical development (VAX-31 covers 31 serotypes, representing ~95% of adult IPD).
Proprietary XpressCF cell-free platform enables precise, site-specific conjugation and carrier-sparing design, avoiding carrier suppression.
Pivotal Phase 3 adult program (OPUS-1) is fully enrolled with topline data expected in Q4 2026, providing a near-term high-impact catalyst.
Strong institutional backing (~97% institutional ownership) and robust cash position to fund operations through key clinical readouts.

Key Investment Risks

Clinical-stage risk: Vaxcyte is currently unprofitable and pre-revenue, with valuation heavily tied to binary clinical trial outcomes.
Regulatory hurdles: Potential delays in FDA BLA submission or review timelines for VAX-31.
Commercial competition: Established players like Pfizer (Prevnar 20) and Merck (Capvaxive) have dominant market positions and extensive commercial infrastructure.

Thesis Invalidation Triggers

Failure of VAX-31 to demonstrate noninferiority to Prevnar 20 in the OPUS-1 Phase 3 trial.
Unanticipated serious adverse events (SAEs) in the OPUS Phase 3 clinical program.
Significant delays in the buildout or regulatory validation of the custom PCV fill-finish line at the North Carolina facility.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.